Conversion surgery after BRAF-directed therapy for unresectable papillary thyroid carcinoma with severe tracheal invasion.

Auris Nasus LarynxJul 30, 2026 (epub)
Case ReportOncology (Medical)Otolaryngology (ENT)General Surgery

Ryoga Ichikawa, Masato Yamada, Keitaro Ae et al.

✦ AI-curated · Sources linked

Case in brief

A 75-year-old man with locally advanced papillary thyroid carcinoma (PTC) presented with severe tracheal invasion and suspected carotid artery involvement, rendering the tumor initially unresectable. After identifying a BRAF V600E mutation, he was treated with dabrafenib and trametinib, leading to significant improvement in airway stenosis. This allowed for successful conversion surgery, which included total thyroidectomy and tracheal resection, with an uneventful recovery.

Diagnostic / clinical pearl

BRAF-directed therapy can facilitate conversion surgery in patients with advanced papillary thyroid carcinoma, particularly those with significant airway invasion.

Why it matters

This case highlights the potential of targeted therapy to transform the management of unresectable thyroid cancers, offering new avenues for surgical intervention.

Source

PubMed · PMID 42532726

Published in Auris Nasus Larynx. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.